The reiterated Buy rating and maintained $38 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Iovance Biotherapeutics. This news is directly related to the company and is important for investors, as it suggests potential upside in the stock price. The confidence in the analysis is high due to the analyst's expertise and the clear stance on the stock.